The US Food and Drug Administration and the oncology community are pushing back against concerns that the agency's breakthrough therapy designations convey lower approval standards on the products that receive them.
With drug pricing and access to therapies a popular issue and payers not immediately offering reimbursement for some FDA-approved therapies,...








